Sie suchten nach: micromol (Englisch - Maltesisch)

500 micromol/ ml
500 mikromol/ ml

optimark 500 micromol/ml solution for injection in vial
optimark 500 mikromol/ml soluzzjoni għall-injezzjoni f’kunjett

optimark 500 micromol/ ml solution for injection in a vial
optimark 500 mikromol/ ml soluzzjoni għall- injezzjoni f’ kunjett

optimark 500 micromol/ml solution for injection in vial gadoversetamide
optimark 500 mikromol/ml soluzzjoni għall-injezzjoni f’kunjett gadoversetamide

1 ml contains 330.9 mg gadoversetamide, equivalent to 500 micromol.
1 ml fih 330.9 mg ta’ gadoversetamide, ekwivalenti għal 500 mikromol.

optimark 500 micromol/ ml solution for injection in a vial gadoversetamide
optimark 500 mikromol/ ml soluzzjoni għall- injezzjoni f’ kunjett gadoversetamide

optimark 500 micromol/ml solution for injection in pre-filled syringe
optimark 500 mikromol/ml soluzzjoni għall-injezzjoni f’siringa mimlija għal-lest

optimark 500 micromol/ ml solution for injection in a pre-filled syringe
optimark 500 mikromol/ ml soluzzjoni għall- injezzjoni, f’ siringa mimlija għal- lest

optimark 500 micromol/ml solution for injection in pre-filled syringe gadoversetamide
optimark 500 mikromol/ml soluzzjoni għall-injezzjoni f’siringa mimlija għal-lest gadoversetamide

optimark 500 micromol/ ml solution for injection in a pre-filled syringe gadoversetamide
optimark 500 mikromol/ ml soluzzjoni għall- injezzjoni f’ siringa mimlija għal- lest gadoversetamide

optimark 500 micromol/ ml solution for injection in a pre-filled syringe gadoversetamide iv use.
optimark 500 mikromol/ ml soluzzjoni għall- injezzjoni f’ siringa mimlija għal- lest gadoversetamide użu għal ġol- vini.

in vitro, glivec inhibits paracetamol o-glucuronidation with ki value of 58.5 micromol/l.
in-vitro, glivec jinibixxi paracetamol o-glucuronidation b’valur ki ta’ 58.5 mikromol/l.

a more restricted tyrosine and phenylalanine diet should be implemented in case the plasma tyrosine level is above 500 micromol/ l.
dieta iktar ristretta ta ’ tyrosine u phenylalanine għandha tiġi implimentata fil- każ li l- livell ta ’ tyrosine fil- plażma jkun iktar minn 500 micromol/ l.

gadoversetamide has been tested in humans in doses up to 700 micromol/kg (seven times the standard dose).
gadoversetamide kien ittestjat fil-bnedmin f’dożi sa massimu ta’ 700 mikromol/kg (seba’ darbiet iktar mid-doża standard).

there was no systematic difference in any of the kinetic parameters as a function of dose level (100 to 700 micromol/kg).
ma kien hemm ebda differenza sistematika fl-ebda wieħed mill-parametri kinetiċi bħala funzjoni tal- livell tad-doża (100 sa 700 mikromol/kg).

colestilan was also associated in dose-dependent reduction in serum uric acid, with a mean reduction of 43 micromol/l after one year of treatment.
colestilan ġie assoċjat ukoll ma’ tnaqqis li jiddependi fuq id-doża fil-uric acid fis-serum, bi tnaqqis medju ta’ 43 micromol/l wara sena ta’ kura.

in the clinical studies, patients with serum creatinine > 400 micromol/l or > 4.5 mg/dl were excluded.
fl-istudji kliniċi, pazjenti li kellhom krejatinina fis-serum ta’ >400 micromol/l jew >4.5 mg/dl kienu esklużi.

still, after 72 hours even in patients with severe renal impairment nearly the whole dose is recovered in the urine and in healthy populations up to 500 micromol/kg doses were administered without safety issues.
madankollu, xorta waħda wara 72 siegħa, anke f’pazjenti b’indeboliment serju tal-kliewi, kważi d-doża kollha tkun irkuprata fl-awrina, u f’popolazzjonijiet f’saħħithom ingħataw dożi sa 500 mikromol/kg mingħajr ma kien hemm problemi ta’ sigurtà.

the agent should be administered as a bolus peripheral intravenous injection at a dose of 0.2 ml/kg (100 micromol/kg) body weight.
is-sustanza għandha tingħata bħala injezzjoni ġol-vina periferali bolus f’doża ta’ 0.2 ml/kg (100 mikromol/kg) ta’ piż tal-ġisem.

gadolinium containing mri contrast agents (gadolinium-based chelates) are designed to act indirectly on the local magnetic environment by altering proton t1 (spin-lattice) and t2 (spin-spin) relaxation times and at the usual concentration of 100 micromol/kg, the t1 shortening predominates, and the t2 shortening is not significant using t1-weighted sequences.
sustanzi tal-kuntrast tal-mri li fihom gadolinium (kelati bbażati fuq gadolinium) huma maħsuba biex jaġixxu indirettament fuq l-ambjent manjetiku lokali billi jibdlu l-ħinijiet tar-rilassament tal-proton t1 (spin-lattice) u t2 (spin-spin) u fil-konċentrazzjoni normali ta’ 100 mikromol/kg, it-tnaqqis ta’ t1 hu predominanti u t-tnaqqis tat-t2 mhuwiex sinifikanti bl-użu ta’ sekwenzi weighted t1.